NeoGenomics Inc (NEO)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	538,198	537,475	536,755	536,037	535,322	534,609	533,898	533,189	532,483	531,779	531,077	530,378	168,120	166,440	164,544	90,605	91,829	93,027	94,250	90,995
Total assets	US$ in thousands	1,681,230	1,678,240	1,695,110	1,709,170	1,740,030	1,755,580	1,792,110	1,829,550	1,869,780	1,906,390	1,896,310	1,494,410	988,331	959,428	945,485	732,247	709,506	711,155	696,667	533,343
Debt-to-assets ratio		0.32	0.32	0.32	0.31	0.31	0.30	0.30	0.29	0.28	0.28	0.28	0.35	0.17	0.17	0.17	0.12	0.13	0.13	0.14	0.17

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $538,198K ÷ $1,681,230K
= 0.32

Neogenomics Inc.'s debt-to-assets ratio has been relatively stable over the past eight quarters, ranging from 0.29 to 0.32. This ratio indicates that the company finances approximately 29% to 32% of its assets through debt, with the remainder funded by equity. A consistent debt-to-assets ratio suggests that Neogenomics has been maintaining a balanced capital structure and has not significantly increased its reliance on debt to finance its operations and investments. This stability in the ratio indicates that the company has been managing its debt levels effectively while also utilizing its assets efficiently to generate revenue. Overall, Neogenomics Inc.'s debt-to-assets ratio demonstrates a prudent approach to managing its financial leverage.